Prof Min Kim, one of South Korea’s leading vitreoretinal surgeons, notes meaningful advantages in the new BIOM 6 viewing ...

Bausch + Lomb announced that CEO and director Brent Saunders left the company and its board on October 12, 2026. Board ...

Eyecare company Bausch + Lomb (NYSE:BLCO) exceeded in Q3 2026, with revenue up 7.3% year on year to $1.38 billion. The ...

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market open. Here’s what to expect.

Bausch + Lomb (BLCO) has abruptly shifted its leadership, with CEO Brent Saunders departing and board chairman Thomas J.

Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end. He is stepping down immediately from the role – by mutual agreement with the board of directors – ...

Bausch + Lomb Corp. ( BLCO ), a global eye health company, on Wednesday announced a return to profit for the third quarter of fiscal 2026, as revenue increased across all three business segments. The ...

Brent Saunders is stepping down as Bausch + Lomb’s CEO through mutual agreement with the company’s board, Bausch announced Monday. (Mike Coppola/Getty Images) Less than four years after returning to ...

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It ...

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading ...

BLCO is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of BLCO shares has increased $0.09 since the market last closed. This is a 0.43% ...

Please provide your email address to receive an email when new articles are posted on . Appio has worked with Bausch + Lomb since 2010. He was appointed as chairman of the board in August. Thomas J.